Healthtech funding in Q3 2014

European Healthtech startup funding raised during Q3 2014.

In Q3 2014, 27 European Healthtech companies closed 28 funding rounds and raised €244M in equity funding (excluding debt and grants), up 72.6% versus Q3 2013. UK led by capital raised, and Abbvie Biotech Ventures was the most active investor. Data as of 6 Nov 2026.

Equity funding

€244M

+72.6% vs Q3 2013 · excl. debt & grants

Funding rounds

-12.5% vs Q3 2013

Companies

Top country

Rank among sectors

5.5% of sector funding

Top-10 round share

93.6%

of disclosed capital

Funding by month

€ raised vs rounds, by month

Data table

	Funding	Rounds
Jul	€18M	7
Aug	€58M	9
Sep	€170M	12

Top countries

by € raised

Data table

	Healthtech — top countries by capital, Q3 2014
UK	€80M
Switzerland	€75M
Israel	€39M
Netherlands	€18M
Germany	€14M
Finland	€9.0M
France	€5.3M
Denmark	€2.8M

Stage mix

by € raised

Data table

	Healthtech — stage mix, Q3 2014
Series A	€88M
Series D+	€77M
Growth/Late	€39M
Other	€18M
Series B	€10M
Seed	€9.4M
Early VC	€2.7M
Grant	€1.5M

Top deals

largest disclosed rounds in Q3 2014

Company	Stage	Date	Amount
Adaptimmune	Series A	Sep 2014	€79M
Biocartis	Series D+	Sep 2014	€65M
Gamida Cell	Growth/Late	Aug 2014	€26M
MagForce	Other	Aug 2014	€14M
AM-Pharma	Series D+	Sep 2014	€12M
NeuroDerm	Growth/Late	Aug 2014	€12M
Sophia Genetics	Series B	Jul 2014	€10M
Alize Pharma	Series A	Sep 2014	€5.0M
Mint Solutions	Series A	Jul 2014	€4.4M
Blueprint Genetics	Other	Sep 2014	€3.5M
Blueprint Genetics	Seed	Aug 2014	€2.9M
Nanovi	Early VC	Sep 2014	€2.7M
Biotie Therapies	Grant	Jul 2014	€1.5M
Mimetas	Seed	Sep 2014	€1.2M
ConceptoMed	Growth/Late	Aug 2014	€1.1M

View all 28 Healthtech deals in Q3 2014 →

Top investors

most active in Q3 2014, by deal count

← All 2014 Healthtech funding